We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

0 hedge funds and large institutions have $12.4K invested in Aptevo Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

96% less capital invested

Capital invested by funds: $352K → $12.4K (-$339K)

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$94K
2
SM
Sabby Management
Florida
-$63.3K
3
Citadel Advisors
Citadel Advisors
Florida
-$47.4K
4
SSA
Schonfeld Strategic Advisors
New York
-$28.8K
5
Squarepoint
Squarepoint
New York
-$25.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
– -$25.1K – –
State Street
27
State Street
Massachusetts
– -$1.98K – –
TSS
28
Two Sigma Securities
New York
– -$2.04K – –
UBS Group
29
UBS Group
Switzerland
– -$1 – –
Vanguard Group
30
Vanguard Group
Pennsylvania
– -$16.6K – –
1
2

APVO Hedge Fund Activity: Q1 2024 in Review

0 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q1 2024, worth a combined $12.4K — down 96% from $352K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of APVO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $94K sold.

  • 0 institutional investors held Aptevo Therapeutics (APVO) as of Q1 2024, down from 2 in Q4 2023.
  • Funds reported $12.4K of Aptevo Therapeutics stock for Q1 2024, down 96% quarter-over-quarter.
  • 0 funds opened new Aptevo Therapeutics positions in Q1 2024 and 2 closed out, a net change of -2 holders.
  • The largest Aptevo Therapeutics seller in Q1 2024 was Renaissance Technologies, an estimated $94K sold.

Based on aggregated 13F filings for Q1 2024.